{"news_desk": "Business", "print_page": null, "section_name": "Business Day", "subsection_name": "DealBook", "byline": {"original": "By MICHAEL J. de la MERCED", "person": [{"middlename": "J.", "firstname": "Michael", "lastname": "de la MERCED", "rank": 1, "role": "reported", "organization": ""}]}, "abstract": null, "type_of_material": "News", "word_count": "235", "lead_paragraph": "The drugmaker had built itself into a $124 billion powerhouse in large part through repeated deals, for companies like Forest Laboratories.", "pub_date": "2015-07-25T00:00:00Z", "document_type": "article", "slideshow_credits": null, "headline": {"main": "Allergan, in Shift From Buying Spree, Considers a Spin-Off"}, "snippet": "The drugmaker had built itself into a $124 billion powerhouse in large part through repeated deals, for companies like Forest Laboratories.", "multimedia": [], "web_url": "http://www.nytimes.com/2015/07/25/business/dealbook/allergan-in-shift-from-buying-spree-considers-a-spin-off.html", "keywords": [{"rank": "1", "is_major": "N", "value": "Mergers, Acquisitions and Divestitures", "name": "subject"}, {"rank": "2", "is_major": "N", "value": "Allergan Inc", "name": "organizations"}], "blog": [], "_id": "55b2e7fc38f0d839f92b9f6f", "source": "The New York Times"}